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Abstract
Secondary damage following primary spinal cord injury extends pathology beyond the site of initial trauma, and effective
management is imperative for maximizing anatomical and functional recovery. Bisperoxovanadium compounds have
proven neuroprotective effects in several central nervous system injury/disease models, however, no mechanism has been
linked to such neuroprotection from bisperoxovanadium treatment following spinal trauma. The goal of this study was to
assess acute bisperoxovanadium treatment effects on neuroprotection and functional recovery following cervical unilateral
contusive spinal cord injury, and investigate a potential mechanism of the compound’s action. Two experimental groups of
rats were established to 1) assess twice-daily 7 day treatment of the compound, potassium bisperoxo (picolinato) vanadium,
on long-term recovery of skilled forelimb activity using a novel food manipulation test, and neuroprotection 6 weeks
following injury and 2) elucidate an acute mechanistic link for the action of the drug post-injury. Immunofluorescence and
Western blotting were performed to assess cellular signaling 1 day following SCI, and histochemistry and forelimb
functional analysis were utilized to assess neuroprotection and recovery 6 weeks after injury. Bisperoxovanadium promoted
significant neuroprotection through reduced motorneuron death, increased tissue sparing, and minimized cavity formation
in rats. Enhanced forelimb functional ability during a treat-eating assessment was also observed. Additionally,
bisperoxovanadium significantly enhanced downstream Akt and mammalian target of rapamycin signaling and reduced
autophagic activity, suggesting inhibition of the phosphatase and tensin homologue deleted on chromosome ten as a
potential mechanism of bisperoxovanadium action following traumatic spinal cord injury. Overall, this study demonstrates
the efficacy of a clinically applicable pharmacological therapy for rapid initiation of neuroprotection post-spinal cord injury,
and sheds light on the signaling involved in its action.
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Introduction
Few effective treatments exist for traumatic spinal cord injury
(SCI). Difficulties in therapeutic development derive from complex
temporo-spatial management of two pathological phases of SCI:
primary mechanical injury, and secondary damage instigated by,
and succeeding the initial trauma. Secondary injury processes
including inflammation, vascular and axonal disruption, excito-
toxicity, and edema exacerbate the primary damage [1,2] and as
such, effective control over secondary injury is essential for limiting
physical and functional deficits endured after SCI. Following
central nervous system (CNS) trauma, rapid cellular necrosis
occurs at the injury epicenter, while delayed onset of apoptosis and
macroautophagy spread out into the lesion penumbra [3],
contributing to secondary cell death [4,5]. These processes are
regulated, at least in part, by phosphatidylinositol-3-kinase
(PI3K)/Akt signaling, with downstream mammalian target of
rapamycin (mTOR) protein complexes involved in promoting cell
survival and growth. Upon PI3K activation, the pro-survival
kinase, Akt, can be phosphorylated and activated by 39-
phosphoinositide-dependent kinases (PDKs) 1 & 2 [6,7], activating
or inhibiting downstream effectors including mTOR [8], BAD [9],
glycogen synthase kinase 3b (GSK3b) [10], and MDM2 [11]. It is
generally accepted that activation of this pathway is beneficial for
preventing cell death and enhancing cellular processes associated
with growth and proliferation. Following CNS injury, however,
many questions remain concerning the influence of this signaling
pathway, and the cell-specific outcomes such activation imparts in
response to the insult. Following SCI, Akt phosphorylation
decreases at and around the injury epicenter, while a PI3K-
mediated upregulation occurs in neurons peripheral to the injury
core [12]. This phenomenon is also observed following focal
ischemic brain injury, and is considered an endogenous neuro-
protective response of surrounding neurons [13].
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are relatively inactive in spinal cord neurons [14]. The PI3K
antagonist and phosphatase and tensin homologue deleted on
chromosome ten (PTEN), however, is highly expressed in adult
CNS neurons [15,16]. PTEN’s negative regulation of PI3K, and
thus its over-activity, is important for cell cycle regulation, cellular
turnover, and cell motility [17]. Such regulation results from
PTEN’s key function as a phosphatidylinositol (3,4,5)-trispho-
sphate (PIP3) lipid phosphatase, opposing PI3K’s activation of Akt
through removal of a phosphate from PIP3 to form phosphatidy-
linositol (4,5)-bisphosphate (PIP2). The loss of PTEN or its function
is beneficial following CNS injury and disease, promoting axonal
regrowth following SCI [18], reducing motor neuron atrophy [19],
and enhancing neural survival [20,21]. Increased downstream
PI3K/Akt signaling activity is implicated in these effects. Such
evidence suggests a potential alteration in PTEN expression or
activity following SCI. Small-molecule protein tyrosine phospha-
tase (PTP) inhibitors, bisperoxovanadium (bpV) compounds, are
known to promote neuroprotection following thoracic SCI [22],
and Parkinsonian neurodegeneration [23], though no specific
cellular signaling mechanism was investigated in these reports.
bpV compounds specifically and potently inhibit PTEN activity in
vitro [24], and administration in vivo promotes neuroprotection in
various CNS injury models through activation of the PI3K/Akt
pathway [25–27]. Akt activity also negatively influences retrograde
axonal degradation through inhibition of macroautophagy
following axotomy [28], a result potentially promoted through
inhibition of PTEN. Thus, targeting PTEN may be part of the
mechanism of bpV-mediated neuroprotection observed following
spinal trauma.
Pharmacological therapies for SCI are urgently needed; as such
treatments are minimally invasive and can be applied rapidly,
which are crucial for minimizing secondary damage. We
hypothesized that acute bpV administration promotes neuropro-
tection and functional recovery, at least partly, through upregula-
tion of PI3K/Akt activity and downregulation of autophagic
processes following SCI. Using histologic and protein analyses,
and application of a novel forelimb functional assessment, we
examined potassium bisperoxo (picolinato) vanadium (bpV[pic])-
mediated effects on neuroprotection, functional recovery, and the
involvement of Akt/mTOR and autophagic activity following
cervical unilateral contusive SCI. To our knowledge, these findings
are the first to investigate a link between bpV-mediated
neuroprotection and PI3K/Akt/mTOR signaling following SCI.
Materials and Methods
Animals and surgical procedures
Adult female Sprague-Dawley rats (200–250 g, Harlan) (n=40)
were housed in controlled conditions with a 12:12 light:dark
schedule, and access to food and water ad libitum. Prior to surgery,
the animals were anaesthetized intraperitoneally (IP) with
ketamine (40 mg/kg)/xylazine (5 mg/kg), and either a laminec-
tomy only, or unilateral cervical SCI was performed as modified
from Gensel et al. [29]. Briefly, a customized vertebral stabilizer
was set to support the 5
th cervical vertebrae and a partial unilateral
laminectomy was performed to expose the right side of the spinal
cord at the same level. With dura intact, the NYU MASCIS
Impactor [30] (2.5 mm tip, 10 g weight, 12.5 mm height) was
used to inflict a moderate unilateral injury [29]. Sham animals
were excluded from injury. Following surgery, animals received an
injection of 3 mL 0.9% saline subcutaneously for hydration and
were placed in temperature-controlled housing overnight for
monitoring recovery. All surgical and animal handling procedures
were performed as approved under the Guide for the Care and
Use of Laboratory Animals (National Research Council) and the
Guidelines of the Indiana University School of Medicine
Institutional Animal Care and Use Committee (Approval
#0000003163).
Drug Treatment
Two sets of rats were randomly designated for treatment with
bpV(pic) (n=14) (Enzo Life Sciences), with dosing modified from
Zhang et al., [20] or vehicle (n=12). After surgery and/or injury,
these animals received an immediate IP injection of 400 ı `g/kg
bpV(pic) while a control group received 0.9% saline (vehicle). A
third group served as a surgical control group (sham) also injected
with vehicle according the prescribed dosing schedule (n=14).
Animals received a second dose of vehicle or bpV(pic) 2 hrs post-
injury, and twice daily for 1 or 7 days thereafter.
Western Blotting
Protein analysis followed procedures described previously [31–
33] with modification. Briefly, a 10 mm spinal cord segment
containing the injury epicenter was removed for protein extraction
24 hours following SCI. Equal protein concentration from each
sample was loaded onto 8–10% polyacrylamide gels, separated by
SDS-PAGE, and transferred to a polyvinylidene difluoride (PVDF)
membrane by electrophoresis. The membranes were immuno-
blotted with the following primary antibodies: monoclonal mouse-
anti PTEN (1:200); monoclonal mouse anti-ribosomal protein S6
(1:200) (Santa Cruz Biotechnologies); polyclonal rabbit anti-
phospho Akt (Ser
473) (1:1,000), a marker used for assessing PI3K
activation; monoclonal mouse anti-pan Akt (1:1,500); polyclonal
rabbit anti-phospho ribosomal protein S6 (Ser
235/236) (1:400) (Cell
Signaling, Inc.), an indicator of mTOR activity; polyclonal rabbit
anti-LC3B (1:100; Abgent), to assess autophagy activity; mono-
clonal mouse anti-b-tubulin (1:1000; Sigma-Aldrich) as a loading
control. Membranes were incubated with a goat anti-rabbit or
anti-mouse fluorescent secondary antibody, fluorescing at either
680 nm or 800 nm wavelength (1:10,000; Rockland Immuno-
chemicals, Inc.) and visualized using the Li-Cor Odyssey infrared
imaging system and software (Version 1.2) per the manufacturer’s
instructions. Quantification of detected bands was performed by
densitometry using ImageJ software (NIH).
Histological Assessments
Six weeks post-injury, tissue was collected and processed as
previously published [34]. In brief, a 1 cm segment of cervical
cord including the injury epicenter was dissected and sectioned
longitudinally in the horizontal plane or transversely at 20 ı `m
thickness on Superfrost Plus slides (Fisher Scientific) using a
cryostat (Leica). Tissue was stained using cresyl violet acetate stain
with eosin counterstaining. Lesion and cavity volume were
calculated using Neurolucida software (MicroBrightfield, Inc.).
Serial sections with an interval of 0.5 mm along the length of the
cord were used for lesion volume measurement and calculation,
spanning from tissue first showing identifiable lesion, to the last
demonstrating such morphology. These same methods, equip-
ment, and software were used to construct 3-dimensional
representations of vehicle- and bpV-treated animal spinal cord
tissue. Additionally, the same sections and staining used for
assessing lesion, cavity, and spared tissue volume were used to
quantify the number of motorneurons throughout the specified
spinal cord distance (3 mm rostral and caudal to the epicenter). To
define a standard anatomical area for counting motorneurons, a
horizontal line was drawn from one side of the transverse section
to the other passing through the central canal. All clearly
Bisperoxovanadium and Neuroprotection Post-SCI
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visible nuclei in plane, and dark, evenly distributed cresyl violet
staining, were manually quantified using ImageJ software.
Vascular Quantification
Six weeks post-injury, spinal tissue sections 2 mm rostral and
caudal, as well as from the epicenter of the lesion, were utilized for
vascular quantification using a general rat endothelial cell marker,
and calculation of the vessel-positive area in the ipsilateral and
contralateral gray matter in vehicle- and bpV-treated animal
groups. In brief, vessels in spinal tissue from bpV- and vehicle-
treated animals were labeled via immunofluorescence with mouse
anti-rat endothelial cell antigen-1 (RECA-1, 1:200; ABD Serotec),
a specific vascular marker, overnight at 4uC. The following day,
the tissue was labeled with fluorescent secondary antibody, and
high power images were acquired with an Olympus BX60
microscope and PictureFrame software (Optronics). RECA-1
+
area was quantified using ImageJ software through methods
modified from previous publication [22]. Briefly, the anatomically
defined area of ipsilateral gray matter containing RECA-1
+
vasculature was outlined and calculated per measured section.
Only areas of gray matter clearly containing vasculature, as
identified by RECA-1 labeling, were included in this assessment.
Immunofluorescence Double Labeling
Immunofluorescence double labeling was performed as previ-
ously described [34]. Briefly, 1 day following SCI, 1 cm spinal
tissue including the injury epicenter was removed after perfusion,
and cryoprotected in 30% sucrose in 0.1 M PBS. Cord segments
were sectioned and prepared for staining as described above, and
incubated with the following primary antibodies: mouse and rabbit
anti-PTEN (1:100; Santa Cruz Biotechnologies), rabbit anti-
phospho ribosomal protein S6 (Ser
235/236) (1:400) (Cell Signaling,
Inc.), mouse anti-NeuN (1:200; Chemicon), a marker for neurons;
mouse anti-CC1 (APC-7, 1:25; Calbiochem, Inc.), a marker for
oligodendrocytes; mouse anti-OX42 (1:50; Harlan Sera-lab), a
marker for microglia; and rabbit and mouse anti-glial fibrillary
acidic protein (GFAP, 1:200; Sigma), a marker for astrocytes. The
following day, the sections were incubated with rhodamine- or
fluoroisothiocyanate-conjugated goat anti-rabbit or anti-mouse
antibodies (1:200; Jackson ImmunoResearch Lab). Sections were
coverslip mounted with Fluoromount G combined with Hoechst
33342 (1:100) for nuclear staining. Pre-immune serum was used as
a control to confirm the specificity of the antibody. Images were
obtained with a Nikon TE2000 laser scanning confocal micro-
scope.
Behavioral Testing
For functional assessment, cereal rings of uniform shape, size,
and flavor were provided and arm joint articulation [35],
movement, treat handling, and coordination were assessed while
the animals ate the treat. Each rat was tested in a home cage,
which promoted the most optimal conditions for assessing the
animals’ behavior and performance. Using an 8 point scale, with 8
indicating normal ability and 0 representing no ipsilateral forelimb
treat contact ability, the animals were tested before SCI (baseline),
and once per week for 6 weeks following injury, and were scored
on three separate trials with the three scores averaged (Table S2).
Treat manipulation was defined as apparent and consistent
coordinated handling of the treat by both forelimbs during eating.
The general scoring guidelines and categories for gauging
functional improvement of the forelimb are provided in Tables
S1 & S2. Visual examples of rats from each group eating the cereal
treats are shown in Figure S1.
Statistical Analysis
To determine significance between two groups, a two-tailed
unpaired Student’s t-test was used. Statistical significance between
multiple groups was determined using a one-way ANOVA with
Tukey’s post-hoc analysis. All statistical values were calculated
using GraphPad Prism 5.0 software (GraphPad, Inc.), with a p
value,0.05 considered statistically significant.
Results
bpV(pic) promoted significant neuroprotection following
cervical contusive SCI
To assess whether bpV treatment promoted neuroprotection
following injury, histological analysis was utilized. bpV-treated
animals (n=5) had significantly reduced ipsilateral lesion
(21%61.1 vs. 34%63.0 SEM; p,0.01) and cavity volume
(approx. 67% reduction; p,0.05) compared to vehicle-treated
animals (n=4) (Fig. 1A & B). Sham animals showed no sign of
injury (n=5). In comparison to the relative area of the ipsilateral
cord, spared tissue was significantly increased in bpV-treated
animals compared to vehicle controls (79%61.1 vs. 66%63.0
SEM; p,0.01). Additionally, bpV treatment greatly reduced the
amount of cavitation typically observed in subacute to chronic
phases after contusive SCI, as seen in the vehicle-treated group
(Fig. 1C & D).
Consistent with reduced lesion volume, bpV-treated animals
exhibited a trend of increased ventral horn motorneurons near
the injury epicenter than vehicle-treated animals at 6 weeks post-
injury, with significantly increased motorneurons noted both
2 mm rostral and caudal to the injury epicenter (Fig. 2A).
Representative photomicrographs demonstrating the difference
in motorneuron number in the rostral ipsilateral ventral horn
between untreated and bpV-treated animals are shown in Fig. 2B
and C. As vascular sparing and integrity have been attributed to
bpV-mediated neuroprotection following SCI, using methods of
vascular quantification modified from previous publication [22],
RECA-1
+ vascular area (mm
2) was assessed in anatomical regions
of interest (gray matter) from transverse spinal cord sections
2 mm rostral and caudal, and at the injury epicenter (Fig. 3).
Spinal cord RECA-1
+ (vascular) gray matter area was signifi-
cantly increased in bpV(pic)-treated rats compared to vehicle-
treated animals (p,0.01) both rostral and at the epicenter of the
injury (p,0.05). No difference in gray matter vascular area was
observed caudal to the injury site (Fig. 3). The contralateral gray
matter vascular area, as expected, did not exhibit differences
between treatment groups rostral or caudal to the injury.
However, significantly more vascular area was measured in the
bpV-treated group within the contralateral gray tissue at the
injury epicenter in comparison to the vehicle-treated group
(p,0.05). This outcome was likely a result of neuroprotection
mediated by treatment (data not shown).
Skilled forelimb articulation and coordination improved
following bpV(pic) treatment
To determine whether the observed neuroprotection mediated
by bpV enhanced functional recovery, a novel forelimb behavioral
assessment was used. During the 6 week behavior testing, sham
animals (n=5) achieved perfect scores (8=maximum score)
overall during testing, as expected (Fig. 4A). Animals treated with
bpV (n=5) recovered significant skilled forelimb function and
coordination while eating cereal rings compared to vehicle-treated
animals (n=4) using our independently-developed forelimb
coordination and manipulation test (Fig. 4A & C). bpV-treated
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animals averaged 4.4360.59 by the end of 6 weeks. Scores
obtained during skilled forelimb use demonstrated a highly linear
correlation with arm articulation ability (R
2=0.88; Fig. 4B), as
scored as a subset from a forelimb locomotion test published and
used by Martinez et al. [35].
Figure 1. bpV(pic) reduces lesion size and cavitation following C5 hemicontusion SCI. A) Tissue extracted from rats 6 wks post-SCI
demonstrate reduced lesion and cavitation through Nissl-eosin staining compared to vehicle treated animals. B & C) Graphical representation
showing statistically significant reduction in lesion and cavity volumes, and increased spared tissue following bpV(pic) treatment. D) 3D-
reconstruction from representative cases illustrating the neuroprotective effects of acute bpV(pic) therapy. **, p,0.01; *, p,0.05. n=425. Error
bars=SEM. Scale bar=1 mm.
doi:10.1371/journal.pone.0030012.g001
Figure 2. Acute bpV therapy reduces motor neuron loss following SCI. A) bpV(pic) treatment spared, on average, more ventral horn motor
neurons than vehicle-treatment. Significantly more motor neurons were present in the ventral horn 2 mm rostral and caudal to the lesion epicenter
of bpV(pic) treated animals. B & C) Photomicrographical representation showing Nissl-eosin stained ventral horns of spinal tissue extracted 6 weeks
post-SCI. Sections shown are from 2 mm rostral to the epicenter and demonstrate the increase in motor neurons in bpV-treated animals over vehicle-
treatment. *, p,0.05. n=425. Error bars=SEM. Scale bar=150 mm.
doi:10.1371/journal.pone.0030012.g002
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phospho-S6 after cervical SCI
As we hypothesized that bpV may act through PTEN functional
inhibition for enhancement of neuroprotection and recovery,
immunofluorescence double-labeling of PTEN with various cell
types and structures was performed for identification of potential
cellular targets affected by bpV treatment (Fig. 5). PTEN was
highly expressed in motorneurons (Fig. 5A–C), CC1
+ oligoden-
drocytes (Fig. 5G–I), and OX-42
+ reactive microglia (Fig. 5J–L)
after injury, though some minor expression was seen in reactive
astrocytes post-SCI (Fig. 5D–F). As PTEN inhibition promotes
upregulation of PI3K/Akt/mTOR signaling, cell-specific co-
localization with the mTOR activity marker phosphorylated
ribosomal protein S6 (p-S6) was also performed. In general, p-
S6 expression upregulation was observed in motorneurons
(Fig. 6A–F) of injured animals, as well as hypertrophic reactive
astrocytes (Fig. 6G–L) and oligodendrocytes (Fig. 6M–P) near the
injury site.
bpV(pic) significantly enhanced Akt/mTOR signaling, and
reduced LC3 II/LC3 I protein ratio
For more accurate quantification of bpV’s effects on PI3K/Akt/
mTOR pathway-related protein expression changes in the cervical
spinal cord, Western blot analysis was performed (Fig. 7A). PTEN
expression levels were not significantly different between sham and
1d groups (n=425, each), though a trend in increase was
observed following injury (Fig. 7B). bpV treatment showed no
significant effect on PTEN expression levels (n=425). To
determine whether SCI or bpV(pic) administration influenced
PTEN’s antagonism of PI3K and downstream mTOR activity,
phosphorylated Akt (p-Akt) and p-S6 levels were assessed. 1 day
following SCI, p-Akt significantly decreased in tissue including the
injury epicenter (p,0.01), while p-S6 expression significantly
increased (p,0.05). bpV-treated animals (n=5) recovered p-Akt
expression to near sham levels compared to injury-only and
vehicle-treated animals (n=5) (p,0.05), and elevated p-S6
expression further over sham (p,0.01), but not significantly over
the other groups (Fig. 7C & D). Since mTOR is a known regulator
of autophagy, autophagosome formation was measured by
quantifying downstream microtubule-associated protein light
chain 3 (LC3) protein levels. A band shift during SDS-PAGE
blotting is indicative of LC3 I to LC3 II conversion, and thus an
increase in autophagic activity [36]. The ratio of LC3 II to LC3 I
increased in untreated animals 1d after injury, though this ratio
significantly diminished to near sham levels of expression following
bpV(pic) treatment (p,0.05), suggesting a reversal of autophagic
activity upregulation seen following SCI (Figs. 7E & 8).
Discussion
Neuroprotection and functional recovery promoted by
bpV
As predicted, by 6 weeks post-injury, bpV(pic) drastically
reduced lesion and cavity volume, while increasing spared tissue,
including vasculature, as well as skilled forelimb function over
vehicle-treated control animals. The enhanced amount of
vasculature-containing gray matter tissue could logically result
from overall reduction of lesion and spread of secondary cell death
observed following bpV therapy, or a stimulation of angiogenesis
following this treatment, due to suppression of PTEN activity and
subsequent upregulation of PI3K signaling [37–39]. A second
explanation is that vascular sparing actually contributes to the
overall neuroprotective effects, a hypothesis proposed by Naka-
shima et al. [22] after observing a similar phenomenon following
bpV(phen) treatment for SCI. In support of this explanation, a
recent study by Han et al. [40] showed that angiopoietin-1 and
synthetic C16 peptide treatment spared vasculature by targeting
the vascular endothelium, leading to reduced inflammation,
diminished white matter loss, and functional recovery following
SCI.
bpV also promoted significantly increased forelimb function
compared to vehicle-treated animals beginning two weeks post-
injury (p,0.05) with improvement observed until the end of testing
(p,0.01). These results corresponded well to the significant
neuroprotection observed in this study. Rats utilize proprioceptive
ability to manipulate and eat through coordinated and articulated
forelimb activity, allowing for a more sensitive assessment of the
injured forelimb’s functional ability. Also, the rats are innately
motivated to eat the treats, requiring no training and allowing for
easy repetition for multiple trials during each testing period
without the need to fast the animals. A similar though separately
developed test was recently reported by Irvine et al. [41],
underscoring the need for reliable and sensitive assessments of
overall fine forelimb function following cervical SCI. The details of
their test also support the validity of our design, enhancing
confidence that the increased performance during our forelimb
assessment after bpV(pic) treatment is genuine.
Linking bpV to Akt/mTOR signaling following cervical
spinal injury
Though no significant PTEN expression change was observed,
our results show that PTEN is highly expressed in neurons, CC1
+
Figure 3. Significant increase in ipsilateral gray matter
vasculature rostral and at the epicenter of the injury. bpV(pic)-
treated animals demonstrated significantly increased vascular (RECA-1)-
positive area in the ipsilateral gray matter 2 mm rostral and at the
epicenter of the lesion 6 weeks post-SCI. *=central canal in
photomicrographs. No significant difference was observed 2 mm
caudal to the epicenter. **, p,0.01; *, p,0.05. n=425. Error bars=SEM.
Scale bar (Rostral & Caudal)=100 mm; (Epicenter)=150 mm.
doi:10.1371/journal.pone.0030012.g003
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Reactive astrocytes expressed PTEN, albeit minimally, as well,
after cervical SCI, suggesting that multiple cell types may be
targets for bpV(pic) action. Overall p-Akt levels relative to pan-Akt
decreased in cervical spinal tissue (Fig. 7A & C), suggesting that
PTEN activity may increase post-SCI. Pilot data also suggested
PTEN activity is likely increased through day 7 after SCI, with p-
Akt remaining near levels shown for 1 day post-injury, and low-
concentration bpV treatment through this period reversed p-Akt
decrease (data not shown). This information influenced the
experimental design and timeframe for delivering bpV in this
study. Though we observed this reversible downregulation of Akt
phosphorylation 1 day post-injury, an increase in downstream p-
S6 was observed in neurons and increasingly hypertrophic
astrocytes near the injury site (Fig. 6A–L), suggesting that neurons
may upregulate mTOR activity for protein synthesis as a
neuroprotective response, and glia for both neuroprotection and
initiation of a reactive state following the injury, as discussed later
in this section. Despite the increase in p-S6 seen in reactive
astrocytes, no significant difference in GFAP reactivity, used as a
general indicator of reactive astrogliosis, was observed between
treated and non-treated animal groups 6 weeks post-SCI (Fig. S2).
Interestingly, oligodendrocytes highly expressed p-S6 both pre-
and post-injury (Fig. 6M–P), suggesting this mechanism may serve
both a neuroprotective, as well as perhaps a myelin-related
function in these cells. PTEN expression in oligodendrocytes is
involved in maintenance of myelin and axonal integrity, though
not for remyelination as demonstrated through PTEN knock-out
experiments [42].
It is quite striking that neurons and glia drastically upregulate p-
S6 following SCI, contradictory to expectations based on reports
of benefits from PTEN inhibition following CNS injury. The
discrepancy between Akt activity decrease and ribosomal protein
activity increase may result from two different or interacting
mechanisms via cross-talk between PI3K and mitogen-activated
protein kinase (MAPK) signaling. It has been shown that following
SCI, active phosphorylated extracellular signal-regulated kinase
(Erk, MAPK) increased dramatically and rapidly [43]. Activated
isoforms of Erk are known contributors to p70S6 kinase (p70S6K)
upregulation along with mTOR [44], which could explain the
significant increase in p-S6 following SCI, despite the down-
regulation of p-Akt. Active Erk is also known to activate mTOR
through upstream tuberous sclerosis complex 2 (TSC2) inhibition
[45], and on p90 ribosomal protein kinase [46] potentially
influencing p-S6 upregulation. Overall, the enhancement in p-
Akt and p-S6 levels by bpV over non-treated controls provides a
potential mechanism for the action of bpV(pic). However, mTOR-
dependent and independent influences on neuroprotection and
functional recovery are both possible explanations for results
observed during this study.
Targeting translational upregulation through S6 activation may
promote an endogenous neuroprotective response, contributing to
various cellular activities triggered by the insult. This could also
explain the upregulation of mTOR activity implicated in astrocyte
reactivity witnessed here and elsewhere [47] in response to spinal
injury. PTEN expression was not visually abundant in non-injured
astrocytes, but was detected at low-levels in reactive astrocytes 1d
post-injury, consistent with reports observing PTEN in astrocytes
Figure 4. bpV-treatment enhances forelimb functional recovery. A) By 6 weeks post-injury, bpV(pic)-treated rats exhibited significantly
enhanced forelimb function over vehicle-treated animals as scored using an 8-point treat manipulation behavioral scale (6.8 vs. 4.5). Sham animals
scored at or near perfect (8 points) throughout the study. B) Testing scores showed a positive linear correlation with arm joint articulation ability
(R
2=0.88). C) Images portraying a rat grasping and manipulating a flavored cereal ring, the treat used in this assessment. **, p,0.01; *, p,0.05.
n=425. Error bars=SEM.
doi:10.1371/journal.pone.0030012.g004
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Though overall p-Akt levels decrease post-injury near the injury
site, the increase in both p-Akt and p-S6 after bpV treatment
suggests an enhanced benefit of upregulating both pathways,
either through endogenous neuroprotective feedback, or another
mechanism promoting amplification of p-S6 and other cell
responses observed following SCI.
Downregulation of autophagy following bpV treatment
Enhancement of endogenous cell survival mechanisms, such as
autophagic activity, can rapidly stabilize the cell in response to
hypoxic, ischemic, and inflammatory conditions. Autophagy is a
normal cellular phenomenon required for degradation of
organelles and proteins, and can be increased for energy
acquisition when under cell or nutrient stress. Autophagy
dysregulation, however, has been implicated as a cause of
autophagic, or Type II programmed cell death following SCI
[4,5]. Contrasting the popular view that mTOR inhibits
autophagy, p70S6K has been shown to enhance autophagic
activity following mTOR activation [49]. However, this endog-
enous protection mechanism may not suffice to spare the cells
from delayed death post-SCI, or perhaps the stimulation of
autophagic activity proceeds from beneficial to detrimental,
ultimately leading to programmed cell death. A continuum of
biological processes within cells influenced by SCI including
autophagic activity is likely in describing different stages leading
to programmed cell death.
Our results suggest that bpV treatment may serve as an
autophagic ‘‘switch’’ by forcing increased mTOR activation, and
enhancing the inhibitory-actions of mTOR on autophagy. Over-
Figure 5. PTEN cellular localization following injury. A–C) PTEN highly colocalized to MAP2
+ neurons however, PTEN only somewhat
colocalized with D–F) GFAP
+ hypertrophic astrocytes near the lesion (arrow), but highly localized to axons (arrowhead). G–I) CC-1
+ oligodendrocytes,
J–L) both smaller and swollen (arrow) degenerating axons within white matter tracts surrounding the injury, and M–O) OX-42
+ reactive microglia also
expressed considerable PTEN 1d following SCI. n=3. Scale bar=00 mm.
doi:10.1371/journal.pone.0030012.g005
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activity, and mTOR can act directly through regulation of
autophagy-related proteins resulting in non-p70S6K dependent
control of this process [49], supporting our findings and aiding in
our interpretation of these results. If autophagic activity plays a
role in neuronal programmed cell death, then bpV(pic) may act
through PI3K and mTOR to downregulate this process,
preventing the transition towards cell loss.
Figure 6. Phospho-S6 cellular localization following injury. Like PTEN, phospho-S6 (p-S6) colocalized with many cell and structure types 1d
following SCI. p-S6 was expressed very abundantly in A–F) neurons, and G–L) hypertrophic astrocytes following SCI, as well as M–P) oligodendrocytes,
as indicated by arrows. n=3. Scale bar=100 mm.
doi:10.1371/journal.pone.0030012.g006
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PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e30012Figure 7. Effects of bpV(pic) on mTOR and autophagy-related protein analysis 1d post-SCI. A) Western blot profiles from tissue collected
from experimental animals 1d post-SCI. B–E) Quantification of blots shown in A. B) Total PTEN protein expression does not significantly change
following injury, though a mild increase in expression is observed. C) p-Akt levels significantly decrease following injury, and are significantly
increased following bpV (pic) treatment. D) Downstream, p-S6 protein levels significantly increase following injury, and are enhanced further
following bpV treatment. E) LC3 II ratio to LC3 I, an indicator of autophagic activity, is increased following injury, and is significantly reduced following
bpV(pic) therapy. **, p,0.01; *, p,0.05. n=425 per group. Error bars=SEM.
doi:10.1371/journal.pone.0030012.g007
Figure 8. bpV(pic) reduces neuronal autophagosome aggregation. Vehicle-treated rats exhibited dense intracellular LC3-positive
autophagosome aggregation in neurons (arrows). Treatment with bpV promoted a decrease in neuronal autophagosome clustering. n=3. Scale
bar=50 mm.
doi:10.1371/journal.pone.0030012.g008
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Although bpV(pic) is an accepted inhibitor of PTEN activity, it
may also exhibit other unknown functions that may or may not
contribute to effects directly investigated in this study. Bisperox-
ovanadium compounds are inhibitors of PTP activity [50], some
others of which may potentially be influenced by such therapy in
addition to PTEN activity. One example involves indirect
promotion of PTEN activity by bpV-mediated inhibition of the
PTP, Src homology region 2 domain-containing phosphatase-1
(Shp-1), which is known to bind, dephosphorylate, and activate
PTEN [51]. Src protein kinases serve several roles, one of which
being involved in promoting cell survival through PI3K/Akt
signaling [52]. Therefore, bpV could interfere with Src-related
protein modulation of PTEN activity in addition to, or separate
from, direct PTEN functional inhibition.
PTEN/PI3K signaling is ubiquitous throughout the body;
therefore, interfering with PTEN inhibition of PI3K signaling may
have effects on unintended cellular targets. This is important in the
spinal cord, in that glia and neurons respond differently to trauma.
Astrocytes and microglia activation parallels the progression of
secondary damage processes that promote neuronal death. For
instance, it has been shown that astrocytes increasingly upregulate
mTOR signaling [47] and downregulate PTEN expression [48] in
response to SCI. PI3K and downstream signaling often interacts with
other cell signaling cascades, such as MAPK-Erk signaling [44,45],
which has its own repertoire of intracellular effects, presenting the
possibility of unintended outcomes. Figure 9 depicts a schematic
diagram of the proposed mechanism of bpV action in this study,
including potential cross-talk between Erk and PI3K/Akt/mTOR
signaling.
Along these lines, PTEN deletions and mutations are commonly
associated with cancer, as the loss of PTEN antagonism of PI3K
dysregulates the balance between cellular senescence and
proliferation [53–55]. To minimize such concerns, short-term
bpV-therapy allows strict control of timing, dosing, and with-
drawal of use of the drug. In the present study, a one-week
treatment regimen of bpV(pic) promoted significant long-term
neuroprotective effects and functional abilities of the forelimb
following treatment, and such a short therapeutic time period
should have minimal impact on the threat of tumor formation
compared to long-term reduction of PTEN activity or PTEN
deletion. Nonetheless, further studies are necessary to investigate
potential side effects of bpV therapy following SCI. In conclusion,
acute administration of 400 mg/kg bpV(pic) following cervical
contusive SCI afforded anatomical and functional forelimb
benefits, important factors for victims suffering from cervical
injuries [56]. This report is a novel step toward understanding the
mechanism and benefits of bpV treatment on injured spinal tissue
and associated functional outcome, and provides a foundation for
future studies utilizing bpV in combinational therapies for
improving anatomical and functional recovery after cervical SCI.
Supporting Information
Figure S1 Forelimb ability between sham, injured, and
injured with bpV treatment. Representative micrographs
depicting forepaw usage while handling flavored cereal rings
during the forelimb functional assessment. Sham animals demon-
strate the ability to fully grasp and coordinate movement of the
treat between forepaws, while injured non-treated animals
primarily support the treat with the injured flexed paw. bpV-
treated animals demonstrate near-sham ability to handle and
manipulate the treats 6 weeks-post injury.
(TIF)
Figure S2 GFAP labeling intensity is not significantly
different 6 weeks post-SCI between treatment groups.
Relative intensity of ipsilateral GFAP intensity is similar between
vehicle- and bpV-treated animal groups, suggesting bpV treatment
Figure 9. Potential mechanistic explanation for bpV(pic)-mediated neuroprotective effects. PTEN’s phosphatase activity converts
phosphatidylinositol (3,4,5)-trisphosphate (PIP3) into phosphatidylinositol (4,5)-bisphosphate (PIP2), thus inhibiting downstream Akt and mTOR
signaling. PI3K converts PIP2 into PIP3, which can then activate Akt and mTOR, thus enhancing p-S6 expression and contributing to the decrease in
cellular autophagic activity that may be involved in programmed cell death, and leading to neuroprotection.
doi:10.1371/journal.pone.0030012.g009
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n=425. Scale bar=0.5 mm.
(TIF)
Table S1 Forelimb Assessment Scoring Guide.
(PPT)
Table S2 Forelimb Assessment Score Sheet.
(PPT)
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